Iconovo Cash Flow Conversion Efficiency

Latest as of June 2026: -0.057x

Iconovo cash flow conversion efficiency. Based on the latest financial reports, Iconovo (ICO) has a cash flow conversion efficiency ratio of -0.057x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-8.48 Million ≈ $-913.01K USD) by net assets (Skr149.29 Million ≈ $16.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Iconovo (2016–2025)

Cash flow conversion efficiency of Iconovo from 2016 to 2025. This chart illustrates how Iconovo's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ICO live share price for real-time trading data and today's change.

Iconovo Cash Flow Conversion Ratio Explained

Iconovo cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Iconovo Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Iconovo ranked by their cash flow conversion efficiency. Also see Iconovo (ICO) market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Greenland Mines Ltd
NASDAQ:GRML
-0.113x
Avillion Bhd
KLSE:8885
-0.004x
Spolytech Co. Ltd
KQ:050760
0.084x
Eurocastle Investment Ltd
AS:ECT
-0.015x
Oceanic Beverages Co Inc
TW:1213
-0.090x
Atlantis Yatirim Holding AS
IS:ATSYH
-0.001x
Cannabist Company Holdings Inc
NEO:CBST
0.161x
Sri Adhikari Brothers Television Network Limited
NSE:SABTNL
-36.713x

Annual Cash Flow Conversion Efficiency for Iconovo (2016–2025)

The table below shows the annual cash flow conversion efficiency of Iconovo from 2016 to 2025. Review ICO free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr117.92 Million
≈ $12.69 Million
Skr-31.87 Million
≈ $-3.43 Million
-0.270x -42.31%
2024-12-31 Skr129.21 Million
≈ $13.91 Million
Skr-24.54 Million
≈ $-2.64 Million
-0.190x +44.15%
2023-12-31 Skr113.53 Million
≈ $12.22 Million
Skr-38.60 Million
≈ $-4.15 Million
-0.340x +30.53%
2022-12-31 Skr89.29 Million
≈ $9.61 Million
Skr-43.70 Million
≈ $-4.70 Million
-0.489x -509.02%
2021-12-31 Skr137.03 Million
≈ $14.75 Million
Skr-11.01 Million
≈ $-1.19 Million
-0.080x +53.31%
2020-12-31 Skr92.73 Million
≈ $9.98 Million
Skr-15.96 Million
≈ $-1.72 Million
-0.172x -54.97%
2019-12-31 Skr108.79 Million
≈ $11.71 Million
Skr-12.08 Million
≈ $-1.30 Million
-0.111x -599.12%
2018-12-31 Skr63.99 Million
≈ $6.89 Million
Skr-1.02 Million
≈ $-109.38K
-0.016x +86.88%
2017-12-31 Skr31.52 Million
≈ $3.39 Million
Skr-3.82 Million
≈ $-410.77K
-0.121x -117.56%
2016-12-31 Skr8.73 Million
≈ $939.49K
Skr6.02 Million
≈ $647.74K
0.689x --

About Iconovo

ST:ICO Sweden Medical Devices
Market Cap
$12.42 Million
Skr115.41 Million SEK
Market Cap Rank
#26344 Global
#545 in Sweden
Share Price
Skr1.20
Change (1 day)
-3.61%
52-Week Range
Skr0.93 - Skr1.75
All Time High
Skr95.00
About

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreeme… Read more